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Erythropoiesis stimulating agents (ESA) treatment failure is associated with poor prognosis for patients with IPSS(1) low and intermediate-1 ("lower risk") myelodysplastic syndromes (MDS)(2) and, to date, there is no standard treatment option in that situation. In this subgroup of patients, disease modifying approaches may be needed to change the evolution(3). Azacitidine (AZA) improve survival in patients with higher risk MDS (4) , although the majority of responses are limited to haematological improvement (HI). This pattern of response fits with the objectives of treatment needed for lower risk MDS who carry other poor prognostic factors, or with resistance to ESAs. Using AZA in those patients (5, 6) , hematological responses (especially erythroid responses) were obtained in 30 to 40% of the cases, but data on survival were limited. We previously reported that the outcome of patients with higher-risk MDS is very poor after AZA failure (7) . The increasing use of AZA for lower risk patients raises the issue of the outcome of such patients following AZA treatment failure. This information will be important to define treatment strategies and to evaluate new agents in clinical trials. In the present report, we examined the outcome of lower risk MDS after failure of azacitidine. in CR at last follow-up (1 year survival estimate= 83%). Overall, there was no survival benefit for being actively treated compared to best supportive care (13 months vs 9 months, p=0.56), but median survival was not reached in patients treated with allogeneic transplantation (p=0.14 vs BSC). Although allografted patients represent a highly selected subset and number of patient were small, those results suggest that allogeneic transplantation should be considered in this situation when feasible and need to be evaluated prospectively.
Despite a relatively small number of patients, our results showed that the outcome of lower risk IPSS patient who have failed AZA is poor with a median OS of 17 months and that WPSS score may be able to predict outcome. A majority of the patients (56%) of our cohort had bone marrow progression after AZA treatment even if median MDS duration before AZA was relatively short (median 13 months) reflecting the severity of the underlying disease in this group of patients. We were not able to demonstrate that active treatment strategy after AZA failure was associated with any survival benefit apart from the potential benefit of allogeneic transplantation. Treatment options following failure of ESAs are limited, in particular in elderly patients unfit for intensive treatments. Besides the potential interest of using IMIDS (10, 11) , investigational agents will have to be tested in that settings (3, 12) . Our data, by determining the outcome of lower risk MDS having failed AZA, provide a background for these future trials. AZA intolerance 2 (3%)
AZA courses are described with the total dose per cycle and we defined 500 mg/m 2 /cycle (corresponding to 95% of the registered 75mg/m²/day for 7 days schedule) as the reference dose. AZA= azacitidine, RBC=red blood cells, WHO=World Health Organization, RA= refractory anemia, RARS refractory anemia with ringed sideroblasts, RCMD refractory cytopenia with multilineage dysplasia, RAEB-1 refractory anemia with excess of blast type 1 IPSS= international prognosis scoring system, WPSS= WHO-based prognosis scoring system *: secondary failure defined all patients that progressed after a first response including disease progression and loss of haematological improvement (HI) SD= stable disease, PD progressive disease B.
